Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SY003
- Development stage
- Preclinical
- Lead developer
- SynRx Therapeutics
- Modality
- Small Molecules
01
Overview
SY003 is a preclinical-stage small molecule drug candidate being developed by Hangzhou SynRx Therapeutics for the treatment of solid tumors. The compound is designed to target DNA damage repair (DDR) pathways, leveraging the concept of synthetic lethality to selectively induce cell death in cancer cells while sparing healthy tissue.
Beyond the preview
Go deeper on SY003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SY003.